Sun Pharmaceutical executes settlement agreement for generic Angiomax in US

02 Apr 2015 Evaluate

Sun Pharmaceutical Industries’ and certain of its subsidiaries have executed settlement agreement with ‘The Medicines Company, USA’ settling the lawsuit filed in the United States against the company and its subsidiaries regarding submission of an Abbreviated New Drug Application (ANDA) by one of subsidiaries, for a generic version of Angiomax, Bivaliruding injection. This product is a direct thrombin inhibitor indicated for use as an anticoagulant.

Under the terms of the settlement agreement, the company’s subsidiary is entitled to launch its version of generic Angiomax in the United States on June 30, 2019 or earlier under certain limited circumstances.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.


Sun Pharma Inds. Share Price

1804.95 -13.65 (-0.75%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×